Richard Scott  Struthers net worth and biography

Richard Struthers Biography and Net Worth

R. Scott Struthers, Ph.D., is our co-founder and has served as our President and Chief Executive Officer since December 2008. Prior to Crinetics, he was senior director and head of endocrinology and metabolism at Neurocrine Biosciences, Inc., from 1998 to 2008. At Neurocrine, he initiated and led the effort to discover and develop orally active, nonpeptide GnRH antagonists, including elagolix. Prior to Neurocrine, from 1995 to 1998, he co-founded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. Between 1992 to 1995 he led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. Dr. Struthers is also a co-founder of the San Diego Entrepreneurs Exchange, a nonprofit organization that provides resources for early-stage start-ups, and he has served on its board of directors since January 2009.

He obtained both his undergraduate and Ph.D. degrees from the University of California, San Diego.

What is Richard Scott Struthers' net worth?

The estimated net worth of Richard Scott Struthers is at least $4.47 million as of November 3rd, 2023. Dr. Struthers owns 135,522 shares of Crinetics Pharmaceuticals stock worth more than $4,472,226 as of December 11th. This net worth evaluation does not reflect any other investments that Dr. Struthers may own. Learn More about Richard Scott Struthers' net worth.

How do I contact Richard Scott Struthers?

The corporate mailing address for Dr. Struthers and other Crinetics Pharmaceuticals executives is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. Crinetics Pharmaceuticals can also be reached via phone at (858) 450-6464 and via email at [email protected]. Learn More on Richard Scott Struthers' contact information.

Has Richard Scott Struthers been buying or selling shares of Crinetics Pharmaceuticals?

During the last ninety days, Richard Scott Struthers has sold $6,083,945.92 of Crinetics Pharmaceuticals stock. Most recently, Richard Scott Struthers sold 199,082 shares of the business's stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $30.56, for a transaction totalling $6,083,945.92. Following the completion of the sale, the chief executive officer now directly owns 135,522 shares of the company's stock, valued at $4,141,552.32. Learn More on Richard Scott Struthers' trading history.

Who are Crinetics Pharmaceuticals' active insiders?

Crinetics Pharmaceuticals' insider roster includes Stephen Betz (Insider), Matthew Fust (Director), Ajay Madan (Insider), and Richard Struthers (CEO). Learn More on Crinetics Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Crinetics Pharmaceuticals?

During the last year, Crinetics Pharmaceuticals insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $110,300.00. During the last year, insiders at the sold shares 12 times. They sold a total of 361,345 shares worth more than $9,528,714.29. The most recent insider tranaction occured on November, 27th when insider Stephen F Betz sold 3,000 shares worth more than $95,520.00. Insiders at Crinetics Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Crinetics Pharmaceuticals.

Information on this page was last updated on 11/27/2023.

Richard Scott Struthers Insider Trading History at Crinetics Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/3/2023Sell199,082$30.56$6,083,945.92135,522View SEC Filing Icon  
7/13/2023Sell14,157$20.35$288,094.95630,805View SEC Filing Icon  
7/11/2023Sell24,384$20.14$491,093.76656,421View SEC Filing Icon  
6/16/2023Sell50,000$20.81$1,040,500.00680,805View SEC Filing Icon  
4/13/2022Sell138,643$26.83$3,719,791.69730,805View SEC Filing Icon  
4/5/2022Sell21,357$25.34$541,186.3857,400View SEC Filing Icon  
9/7/2021Sell30,000$25.00$750,000.00View SEC Filing Icon  
12/2/2020Buy1,000$12.60$12,600.004,000View SEC Filing Icon  
7/15/2020Sell17,500$15.30$267,750.00View SEC Filing Icon  
See Full Table

Richard Scott Struthers Buying and Selling Activity at Crinetics Pharmaceuticals

This chart shows Richard Scott Struthers's buying and selling at Crinetics Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Crinetics Pharmaceuticals Company Overview

Crinetics Pharmaceuticals logo
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $33.00
Low: $32.56
High: $33.75

50 Day Range

MA: $29.45
Low: $25.62
High: $33.50

2 Week Range

Now: $33.00
Low: $15.23
High: $34.09


797,340 shs

Average Volume

769,834 shs

Market Capitalization

$2.20 billion

P/E Ratio


Dividend Yield